On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety

More than 2,000 measles cases have been recorded in the United States this year, according to federal health data, marking the highest annual total the country has seen in several decades.

Active outbreaks, most notably in upstate South Carolina and in communities along the Arizona-Utah border — are continuing to report new infections each week. Health officials warn that this sustained spread could jeopardise the measles elimination status the US has maintained for the past 25 years.

Measles Cases Surge Past 2,000 In The US

As of December 30, a total of 2,065 confirmed measles cases had been reported nationwide in 2026, based on figures released Wednesday by the US Centers for Disease Control and Prevention. The last time annual measles infections crossed the 2,000 mark was in 1992, shortly after public health authorities revised vaccination guidance to recommend two doses of the measles-mumps-rubella (MMR) vaccine for children instead of one.

Measles: How Effective Is The Measles Vaccine?

Measles is among the most infectious diseases known, but it can be prevented through vaccination. The CDC says a single dose of the MMR vaccine is about 93 percent effective at preventing measles, while two doses increase protection to 97 percent. Despite this, immunisation coverage has been slipping steadily over recent years.

Measles In US: Falling vaccination rates raise concern

CDC data shows that during the last school year, only 92.5 percent of children entering kindergarten had received the MMR vaccine. This falls below the 95 percent coverage level that public health experts say is needed to prevent outbreaks and protect communities through herd immunity.

Measles In US: Why Elimination Status Is Now At Risk

The US has been considered measles-free since 2000, a designation that means no continuous chains of transmission have lasted longer than a year. However, several large outbreaks reported this year may be linked, raising concerns that ongoing transmission could persist beyond late January and threaten that status.

One major outbreak that began in West Texas in late January was officially declared over in mid-August. That outbreak led to hundreds of related cases across Texas and New Mexico and resulted in three deaths — two children and one adult — all of whom were unvaccinated.

In early October, South Carolina’s health department confirmed a measles outbreak in the state’s upstate region. Over the past four months, that outbreak has grown to nearly 180 cases and continues to spread. At least 20 new infections have been reported since Friday, and close to 300 people are currently in quarantine due to exposure to confirmed cases.

“We know that many of the cases we are seeing involve people who were already under quarantine because of known exposure,” said Dr Linda Bell, South Carolina’s state epidemiologist, speaking on Tuesday. She added that the virus is spreading within households as well as in schools and churches.

Another significant outbreak remains active along the Utah-Arizona border, where more than 350 measles cases have been reported between the two states so far this year.

Canada Loses Measles-Free Status

In November, the Pan American Health Organization, which operates under the World Health Organization, announced that Canada had lost its measles elimination status due to a large and ongoing outbreak.

“At the same time, the remaining 34 countries in the region continue to hold their measles-free certification,” said PAHO Director Dr Jarbas Barbosa.

Health officials say potential genetic connections between the Texas outbreak earlier this year and the ongoing outbreak in South Carolina could pose a serious challenge to the US designation.

“The trend we are seeing suggests that more cases are likely to occur well into January,” Bell said. “What that means for our national status as a country that has eliminated measles is still uncertain.”

A dangerous superbug that does not respond to most antibiotics is spreading rapidly across the United States, with Alabama reporting 158 cases so far this year. The data, shared by the Alabama Department of Public Health, highlights growing concern among health officials as infections continue to rise in healthcare settings.

The organism, known as Candida auris, is a type of yeast or fungus that can lead to severe and sometimes life-threatening infections. According to the Centers for Disease Control and Prevention, the fungus is especially troubling because it can survive on human skin and hard surfaces for months, even after routine cleaning and disinfection.

Why Candida auris Is Hard to Control

Unlike many other infections, Candida auris can spread easily through shared medical equipment and direct contact between people. Its ability to withstand commonly used disinfectants makes it difficult to eliminate once it enters a healthcare facility.

State health officials say cases have increased every year, pointing to a steady and worrying trend. “Each year, we have seen increases in our case counts which underscores the need for sustained vigilance,” the Alabama Department of Public Health told AL.com.

Superbug Fungus Candida Auris: Nursing Homes Among the Worst Affected

Nursing homes and long-term care facilities are bearing the brunt of the outbreak. According to ADPH, these settings face a higher risk because residents often have weakened immune systems and require frequent medical care.

“At this time, the Alabama Department of Public Health’s primary concern is the potential for unrecognized transmission within and between healthcare facilities,” the department said. Officials fear that infections may spread silently before being detected.

Superbug Fungus Candida Auris: CDC Guidelines and State Response

The health department confirmed via email that it is following the CDC’s recommended containment strategy to limit further spread. Healthcare providers and laboratories in Alabama are voluntarily reporting cases, although the state’s figures are not currently listed on the CDC’s national tracking dashboard, as per USA Today.

Alabama is not alone in dealing with the superbug. Nearby states are also seeing significant numbers. CDC data shows Tennessee has reported 189 cases, Mississippi 108, and Georgia 377. Florida, like Alabama, does not yet have figures publicly listed on the CDC website.

Superbug Fungus Candida Auris: A Growing National Problem

Candida auris was first identified in 2009 and has become increasingly common since then. The CDC said the fungus was first detected in the United States in 2016, when 51 cases were reported. By 2020, that number had climbed to more than 700.

This year, the rise has been sharp. As of December 20, 7,046 cases have been reported nationwide. In 2025 alone, 28 states recorded infections, with Nevada reporting the highest number of cases.

Superbug Fungus Candida Auris: Symptoms and Health Risks

The fungus can infect different parts of the body, including the bloodstream, wounds, and ears. Symptoms vary depending on where the infection occurs and how severe it is. In some cases, people may not show symptoms at all.

The CDC noted that most patients who develop Candida auris infections are already seriously ill. This makes it difficult to determine how much the fungus contributes to death compared to other existing health conditions.

Superbug Fungus Candida Auris: Preventing Further Spread

ADPH stressed that stopping the spread will require strong coordination across healthcare systems. “Continued collaboration with healthcare partners, timely reporting, and adherence to recommended infection control practices are critical to preventing further spread and limiting outbreaks,” the department said.

Health officials say ongoing awareness, strict hygiene measures, and early detection remain the best tools to contain this growing threat.

The central government has announced a decisive regulatory move concerning nimesulide, a widely prescribed non-steroidal anti-inflammatory drug used to treat pain, fever, and inflammation. In an effort to protect public health, the Centre has barred the manufacture, sale, and distribution of oral nimesulide formulations that contain more than 100 mg of the drug. The restriction has come into force with immediate effect and applies across the country, as per NDTV.

The decision follows mounting safety concerns linked to high-dose oral preparations of the medicine. According to the official notification issued by the government, doses exceeding 100 mg may pose a risk to human health. The order also notes that safer and well-established alternatives are already available in the market. Given this, the authorities concluded that continuing the availability of high-dose nimesulide does not serve the public interest.

What Is Nimesulide and Why Is It Prescribed?

Nimesulide belongs to a group of medicines known as non-steroidal anti-inflammatory drugs, or NSAIDs. Doctors commonly prescribe it to manage acute pain, reduce fever, and relieve inflammation associated with conditions such as musculoskeletal injuries, dental pain, or post-surgical discomfort. The drug works by blocking substances in the body that cause pain and swelling, as per Mayo Clinic.

Despite its effectiveness in symptom relief, nimesulide has remained controversial for years due to questions surrounding its safety, especially when used in higher doses or for longer durations. While it continues to be prescribed in India under regulated conditions, its use has been closely watched by health authorities and medical experts.

Legal Basis for the Ban

The prohibition has been issued under Section 26A of the Drugs and Cosmetics Act, 1940. This provision allows the central government to restrict or ban drugs if they are found to be unsafe, ineffective, or harmful to patients. Before finalising the decision, the government sought the opinion of the Drugs Technical Advisory Board, or DTAB, which is the highest advisory body on technical matters related to drugs and cosmetics in India.

After reviewing available scientific data and expert input, the board supported the move, leading to the issuance of the nationwide ban on high-dose oral formulations, as per NDTV.

Safety Concerns and Global Position

Nimesulide has faced sustained scrutiny from regulators and healthcare professionals, primarily due to concerns about liver-related side effects. Several studies and post-marketing surveillance reports have linked the drug to cases of liver toxicity, particularly when used in higher doses.

The World Health Organization has not included nimesulide in its Model List of Essential Medicines, a key reference document that guides countries on priority medicines for basic healthcare needs. This exclusion reflects ongoing global caution around the drug’s safety profile. In fact, regulatory authorities in multiple countries have either restricted its use or removed it from the market altogether after reviewing reports of hepatic injury documented in WHO pharmacovigilance data.

Indian Regulatory Reviews and Safer Alternatives

In India, the Central Drugs Standard Control Organisation has reviewed the risk-benefit balance of nimesulide on several occasions. These reviews were prompted by both domestic data and international findings related to adverse effects. Medical experts in the country have consistently highlighted that alternatives such as paracetamol and ibuprofen offer a more reliable safety record when taken at recommended doses.

These commonly used pain relievers are backed by extensive clinical evidence and guidance from bodies like the Indian Council of Medical Research, which supports their use for pain and fever management under standard dosing protocols.